IP Library Granted Patent US 11,623,916
Granted Patent B2
US 11,623,916 · App. 17/148,817 · Granted Apr 11, 2023

Highly purified batches of pharmaceutical grade migalastat and methods of producing the same

Inventors: Kamlesh Sheth (North Brunswick, NJ); Sergey Tesier (Monroe, NJ); James Cartwright (Middlesex, GB); Clive King (Middlesex, GB); Wendy Cross (Middlesex, GB)
Assignee: Amicus Therapeutics, Inc.
C07D211/46A61J1/035G01N15/0826G01N33/15C07B2200/13G16H20/10
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,623,916
App. No.
17/148,817
Granted
Apr 11, 2023
Kind
B2
Abstract

Provided are methods of producing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of determining the purity of a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of distributing a batch of 1,2,3,6-tetrapivaloyl-D-galactofuranoside; 5-azido-5-deoxy-1,2,3,6-tetrapivaloyl-D-galactofuranoside; intermediate grade migalastat hydrochloride; and/or migalastat hydrochloride. Also provided are methods of assessing suitability of migalastat hydrochloride for medical use.

Claims (54)

1. A method of producing a batch of migalastat hydrochloride, the method comprising:

performing a first crystallization step comprising dissolving intermediate grade migalastat hydrochloride in water and then adding ethanol to induce crystallization, providing a first crystallized migalastat hydrochloride;

performing a second crystallization step comprising dissolving the first crystallized migalastat hydrochloride in water and then adding ethanol to induce crystallization, providing a second crystallized migalastat hydrochloride; and

isolating the batch of migalastat hydrochloride.

2. The method of claim 1 , wherein the first crystallization comprises:

dissolving the intermediate grade migalastat hydrochloride in water at a first crystallization temperature to provide dissolved intermediate grade migalastat;

adding ethanol to the dissolved intermediate grade migalastat to induce crystallization, providing a slurry comprising a first crystallized migalastat hydrochloride;

isolating the first crystallized migalastat hydrochloride when the slurry comprising the first crystallized migalastat hydrochloride reaches a first isolation temperature;

filtering the first crystallized migalastat hydrochloride;

washing the filtered first crystallized migalastat hydrochloride with ethanol; and

drying the washed first crystallized migalastat hydrochloride.

3. The method of claim 2 , wherein the second crystallization comprises:

dissolving the first crystallized migalastat hydrochloride in water at a second crystallization temperature to provide a second dissolved migalastat product;

adding a first portion of ethanol to the second dissolved migalastat product to induce crystallization, providing a slurry comprising a second crystallized migalastat hydrochloride;

adding a second portion of ethanol to the slurry comprising the second crystallized migalastat hydrochloride after a hold time;

isolating the second crystallized migalastat hydrochloride when the slurry comprising the second crystallized migalastat hydrochloride reaches a second isolation temperature;

filtering the second crystallized migalastat hydrochloride;

washing the filtered second crystallized migalastat hydrochloride with ethanol; and

drying the washed second crystallized migalastat hydrochloride to produce the batch of migalastat hydrochloride.

4. The method of claim 1 , wherein the intermediate grade migalastat hydrochloride, the first crystallized migalastat hydrochloride, or both, is dissolved in an amount of water which is from 1.0 to 1.6 times the weight of the corresponding migalastat hydrochloride.

5. The method of claim 4 , wherein the amount of water is from 1.1 to 1.4 times the weight of the corresponding migalastat hydrochloride.

6. The method of claim 4 , wherein the amount of water is 1.3 times the weight of the corresponding migalastat hydrochloride.

7. The method of claim 3 , wherein the first crystallization temperature, the second crystallization temperature, or both, is within a range from 30° C. to 60° C.

8. The method of claim 7 , wherein the first crystallization temperature, the second crystallization temperature, or both, is within a range from 40° C. to 60° C.

9. The method of claim 7 , wherein the first crystallization temperature, the second crystallization temperature, or both, is about 50° C.

10. The method of claim 2 , wherein the amount of ethanol added to the dissolved intermediate grade migalastat is from 1 to 11.4 times the weight of migalastat hydrochloride present in the dissolved intermediate grade migalastat.

11. The method of claim 10 , wherein a total amount of ethanol, added as the first and second portion of ethanol, is from 1 to 11.4 times the weight of migalastat hydrochloride present in the second dissolved migalastat product.

12. The method of claim 11 , wherein the amount of ethanol, the total amount of ethanol, or both, is from 4.8 to 11.4 times the weight of the corresponding migalastat hydrochloride.

13. The method of claim 11 , wherein the amount of ethanol, the total amount of ethanol, or both, is from 8.4 to 10.6 times the weight of the corresponding migalastat hydrochloride.

14. The method of claim 11 , wherein the amount of ethanol, the total amount of ethanol, or both, is about 9.5 times the weight of the corresponding migalastat hydrochloride.

15. The method of claim 11 , wherein the first portion of ethanol is 1.8 to 2.0 times the weight of the migalastat hydrochloride present in the second dissolved migalastat product.

16. The method of claim 15 , wherein the first portion of ethanol is 1.9 times the weight of the migalastat hydrochloride present in the second dissolved migalastat product.

17. The method of claim 3 , wherein the second portion of ethanol is 6.7 to 8.4 weights of ethanol times the weight of the migalastat hydrochloride present in the slurry comprising the second crystallized migalastat hydrochloride.

18. The method of claim 3 , wherein the first isolation temperature, the second isolation temperature, or both, is within a range from 5° C. to 35° C.

19. The method of claim 18 , wherein the first isolation temperature, the second isolation temperature, or both, is about 20° C.

20. The method of claim 2 , wherein the ethanol is added to the dissolved intermediate grade migalastat over a period from 0 to 65 minutes.

21. The method of claim 20 , wherein the ethanol is added over a period of 60 minutes.

22. The method of claim 20 , wherein the first portion of ethanol is added over a period from 5 minutes to 60 minutes.

23. The method of claim 3 , wherein the hold time is from 5 min to 60 min.

24. The method of claim 1 , wherein the batch of migalastat hydrochloride is pharmaceutical grade.

25. The method of claim 3 , wherein the batch of migalastat hydrochloride is pharmaceutical grade.

26. A method of producing a batch of migalastat hydrochloride, the method comprising performing a first crystallization and a second crystallization, wherein:

the first crystallization comprises:

dissolving intermediate grade migalastat hydrochloride in water at a first crystallization temperature to produce dissolved intermediate grade migalastat hydrochloride;

adding ethanol to the dissolved intermediate grade migalastat hydrochloride to induce crystallization, providing a slurry comprising a first crystallized migalastat hydrochloride;

isolating the first crystallized migalastat hydrochloride;

dissolving the first crystallized migalastat hydrochloride in water at a second crystallization temperature to produce a second dissolved migalastat product;

adding a first portion of ethanol to the second dissolved migalastat product to induce crystallization, providing a slurry comprising a second crystallized migalastat hydrochloride;

adding a second portion of ethanol to the slurry comprising the second crystallized migalastat hydrochloride after a hold time; and

isolating the batch of migalastat hydrochloride.

27. The method of claim 26 , wherein the first crystallization temperature, the second crystallization temperature, or both, is within a range from 30° C. to 60° C.

28. The method of claim 26 , wherein the first isolation temperature, the second isolation temperature, or both, is within a range from 5° C. to 35° C.

29. The method of claim 26 , wherein the hold time is from 5 min to 60 min.

30. The method of claim 26 , wherein the batch of migalastat hydrochloride is pharmaceutical grade.

Assignments (6)
SECURITY INTEREST Recorded Apr 27, 2026
From: BIOMARIN PHARMACEUTICAL INC.; AMICUS THERAPEUTICS, INC.
To: CITIBANK, N.A., AS COLLATERAL AGENT
Reel/Frame 075493/0968 →
RELEASE OF SECURITY INTEREST Recorded Apr 27, 2026
From: WILMINGTON TRUST, NATIONAL ASSOCIATION
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 075494/0030 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2024
From: CARTWRIGHT, JAMES; KING, CLIVE; CROSS, WENDY
To: GLAXOSMITHKLINE SERVICES UNLIMITED
Reel/Frame 067645/0899 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2024
From: GLAXOSMITHKLINE SERVICES UNLIMITED; GLAXOSMITHKLINE RESEARCH AND DEVELOPMENT LIMITED; GLAXO GROUP LIMITED
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 067645/0907 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jun 6, 2024
From: SHETH, KAMLESH; TESLER, SERGEY
To: AMICUS THERAPEUTICS, INC.
Reel/Frame 067645/0915 →
SECURITY INTEREST Recorded Oct 6, 2023
From: AMICUS THERAPEUTICS, INC.
To: WILMINGTON TRUST, NATIONAL ASSOCIATION
Reel/Frame 065177/0196 →
Continuity (2)
Provisional Application 63126264 · Dec 16, 2020
Related Publication 20220185776A1 · Jun 16, 2022
Cited By (1)
US 12,275,703